Stakeholder Opinions: Endometriosis - Scientific clarity will unlock market potential
Scope
Report Highlights
Reasons to Purchase
Table of Contents
- ABOUT DATAMONITOR HEALTHCARE - page 2
- About the Women's Health pharmaceutical analysis team - page 2
- CHAPTER 1 EXECUTIVE SUMMARY - page 3
- Scope of the analysis - page 3
- Contributing experts - page 3
- Datamonitor insight into the Endometriosis market - page 4
- Related reports - page 5
- CHAPTER 2 MARKET DYNAMICS - page 7
- Endometriosis market definition - page 8
- Limitations in sizing the endometriosis market with IMS data - page 9
- Current market overview - page 9
- Market size has yet to recover from 2006 fall - page 9
- US market changes have contributed to 7MM market shrink - page 11
- Political changes have boosted sales in Spain - page 12
- POCs are the most common treatment option for endometriosis - page 13
- Lupron remains the most popular GnRH agonist treatment - page 15
- Market size has yet to recover from 2006 fall - page 9
- Endometriosis market definition - page 8
- CHAPTER 3 DISEASE OVERVIEW - page 18
- Definition of endometriosis - page 19
- Classification of endometriosis: Re-AFS - page 20
- Etiology of endometriosis: still not well understood - page 22
- Retrograde menstruation and implantation - page 23
- Lymphatic/vascular dissemination - page 23
- Developmental coelomic metaplasia - page 24
- Genetic predisposition - page 24
- Environmental factors - page 25
- Immunological susceptibility - page 25
- Dynamic progression of endometriosis - page 26
- Recurrence in endometriosis - page 27
- Symptoms of endometriosis - page 27
- Epidemiology of endometriosis - page 29
- Socio-demographic contributors to endometriosis prevalence - page 29
- Limitations of endometriosis epidemiology analysis - page 30
- Factors specific to endometriosis: - page 30
- Factors generalized to all epidemiology analysis: - page 32
- The gold standard endometriosis epidemiology study - page 32
- Prevalence estimates: the general versus gynecologic population - page 33
- Prevalence of endometriosis in the general population is assumed to be 10% - page 35
- Prevalence of endometriosis in the gynecologic population may be more representational - page 35
- Unmet need in endometriosis - page 42
- Understanding the etiology of endometriosis will aid the development of prophylactic and specific treatments - page 43
- Non-invasive diagnostic procedures will lower morbidity - page 45
- Physician education will quicken time to diagnosis - page 46
- Patient education promotes treatment seeking - page 47
- Better pain management concepts will help women cope - page 47
- Definition of endometriosis - page 19
- CHAPTER 4 TREATMENT TRENDS - page 49
- Endometriosis patient diagnosis and referral algorithm - page 50
- 'Under-diagnosed and over treated' - page 50
- Treatment of endometriosis - page 51
- Combined oral contraceptives: first-line therapy - page 53
- Short term efficacy is similar to that of GnRH agonists - page 53
- Progestogen treatments are most commonly used therapy - page 55
- Antiprogestogen use is limited to gestrinone - page 56
- Androgens: Danazol-first treatment indicated for endometriosis - page 57
- Efficacious for pain relief - page 58
- Side effects limit usefulness of product - page 59
- Danazol remains useful for niche patients - page 60
- GnRH agonists: short-term efficacy at the expense of side effects - page 61
- Characteristics of successfully marketed GnRH agonists - page 62
- Lupron: the 'gold standard' - page 64
- Lupron with add-back makes side effects more manageable - page 66
- Surgery for severe and non-responsive endometriosis - page 68
- Laparoscopic surgery: a range of techniques can reduce pain - page 68
- Hysterectomy: the last treatment option - page 69
- Combined oral contraceptives: first-line therapy - page 53
- Patient treatment goals - page 69
- Pain reduction - page 70
- Pregnancy - page 71
- Endometriosis patient diagnosis and referral algorithm - page 50
- CHAPTER 5 RESEARCH AND DEVELOPMENT - page 73
- The ideal drug for the treatment of endometriosis - page 74
- Efficacy must prevent recurrence - page 74
- Safety essential in a young patient population - page 75
- Side-effects profile must be improve compliance - page 75
- Cost must be kept low for long-term use - page 76
- Pipeline overview - page 77
- Considerable variety in mechanism, delivery mode, and manufacturer - page 77
- Large pipeline is beginning to mature - page 79
- New methods of drug delivery attempt to fulfill unmet need - page 80
- Nasal administration may be hindered by unwelcome irritation - page 81
- Vaginal route unpopular in conservative patient population - page 81
- Late-stage products offer some hope to patients - page 82
- Visanne progestogen could benefit from specific endometriosis label - page 82
- Balance will need marketing partner to realize Libra's full potential - page 84
- FP-1096 benefits from a novel drug delivery technique - page 85
- Mechanisms of action of pipeline products - page 86
- Aromatase inhibitors may offer long-term remission - page 88
- Chemokine receptor antagonists center on inflammatory and immune response - page 88
- Immunomodulators are still regarded warily - page 89
- Combination products will not radically alter treatment - page 89
- Promising estrogen receptor beta agonists require more research - page 90
- GnRH antagonists have important advantages over agonists - page 91
- Progestogen agonists are as effective as marketed therapies - page 93
- Selective progestogen receptor modulators - page 94
- Clinical trial design in endometriosis - page 95
- Difficulties inherent in clinical trials of endometriosis therapies - page 95
- Patient recruitment must be carefully considered - page 97
- Endpoints in clinical trial design - page 98
- Arguably pain is the endpoint of most relevance to the patient - page 98
- That lesion size should be a secondary endpoint is a contentious issue - page 99
- Quality of life scale expands on the endpoint of pain - page 100
- Difficulties inherent in clinical trials of endometriosis therapies - page 95
- The ideal drug for the treatment of endometriosis - page 74
- CHAPTER 6 CURRENT MARKET ISSUES - page 102
- Raising the profile of endometriosis - page 103
- Breaking the taboo - page 103
- Raising awareness: lessons from other disease areas - page 104
- The EEA takes the lead in lobbying in Europe - page 105
- Breaking the taboo - page 103
- Current issues in diagnosis of endometriosis - page 107
- Biomolecular and genetic diagnostics are desirable but not trusted - page 108
- Current research - page 108
- CA-125 testing has had a mixed response - page 109
- Imaging diagnostics currently offer the most promise - page 111
- Biomolecular and genetic diagnostics are desirable but not trusted - page 108
- The endometriosis indication - page 112
- Physicians find specific labeling increasingly useful - page 114
- The potential of endometriosis as a secondary indication - page 114
- Uterine fibroids - page 115
- Menorrhagia (excessive bleeding) - page 116
- Raising the profile of endometriosis - page 103
- BIBLIOGRAPHY - page 117
- Journal papers - page 117
- Websites - page 127
- APPENDIX - page 130
- IMS data - page 130
- Medical sales data caveats - page 130
- Medical sales data methodology - page 130
- Contributing experts - page 131
- About Datamonitor - page 131
- About Datamonitor Healthcare - page 131
- Datamonitor Healthcare's therapy area capabilities - page 132
- About the Disease analysis team - page 133
- Disclaimer - page 134
- IMS data - page 130
- List of Tables
- Table 1: ICD-10 codes used to define the endometriosis market - page 8
- Table 2: Frequency and location of endometriosis implants in the pelvis - page 20
- Table 3: Frequency of symptoms among surgically diagnosed endometriosis patients, 2007 - page 28
- Table 4: Common symptoms of endometriosis and other conditions - page 29
- Table 5: Epidemiology overview of endometriosis, 2007 - page 34
- Table 6: Endometriosis prevalence in the 7MM general population, 2007 - page 35
- Table 7: Endometriosis prevalence in the CPP (gynecological) population, 2007 - page 37
- Table 8: Endometriosis prevalence in the infertile (gynecologic) population across the seven major markets, 2007 - page 41
- Table 9: Summary of endometriosis treatment with danazol - page 58
- Table 10: Endometriosis-specific sales of GnRH agonists in the seven major markets combined, by molecule, 2006-07 - page 62
- Table 11: Cost of select GnRH agonists in the UK, 2007 - page 63
- Table 12: Lupron product range, 2007 - page 64
- Table 13: Overview of the endometriosis pipeline, 2007 - page 77
- Table 14: Mechanism of action of the drugs in the endometriosis pipeline, 2007 - page 87
- Table 15: Action taken by the European Endometriosis Alliance in H1, 2007 - page 106
- List of Figures
- Figure 1: The seven major endometriosis markets by country, 2003-07 - page 10
- Figure 2: The five major European (EU) endometriosis markets. 2003-07. - page 11
- Figure 3: Seven major endometriosis market size, split by region, 2003--07 - page 12
- Figure 4: Volume sales of products within endometriosis treatment types in the seven major markets combined, 2007 - page 14
- Figure 5: Market share and market growth of key GnRH agonists in the seven major endometriosis markets, 2006-07 - page 16
- Figure 6: Prevalence of CPP and endometriosis in the female population and prevalence of endometriosis in the CPP population (000s), 2007 - page 38
- Figure 7: Causes of infertility for US couples undergoing assisted reproductive technology using fresh, non-donor eggs or embryos, 2004 - page 40
- Figure 8: Prevalence of infertility and endometriosis in the female population and prevalence of endometriosis in the infertile population (000s), 2007 - page 42
- Figure 9: Unmet needs in endometriosis as identified by key opinion leaders, 2007 - page 43
- Figure 10: Patient diagnosis referral pathway in endometriosis, according to key opinion leaders, 2007 - page 51
- Figure 11: Side-effect versus efficacy profile of key treatments on the endometriosis market according to interviewed EU and US opinion leaders, 2007 - page 52
- Figure 12: An endometriosis patient treatment pathway dependent on treatment goal - page 70
- Figure 13: Frequency of products in the pipeline, by development stage, 2007 - page 79
- Figure 14: Breakdown of pipeline products by delivery method, where known, in 2007 - page 80
Other users found this report page using the following search terms: endometriosis endometriosis market visanne size scientific treatment prevalence current diagnosis celebrity
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.